Safety and tolerability of PCSK9i and ANGPTL3i in HoFH
patients
At the end of the follow-up period, no significant difference was
observed between the groups with regards to the prevalence of TEAE or
treatment discontinuation (p > 0.05 for both). The
prevalence of gastroenteritis, abdominal pain, nausea, and vomiting was
higher, while injection site reactions, upper respiratory tract
infections, and elevated creatine kinase were less prevalent in the
ANGPTL3i group compared to PCSK9i (p > 0.05 for all). Other
adverse clinical events were not significantly different between the
groups (Table 2 ).